HEALTH TECHNOLOGY
CORPORATE GOVERNANCE
Guardant Health Grants RSUs to 149 New Employees Under Nasdaq Inducement Listing Rule
46,044
RSU SHARES GRANTED
1/3 Annually
VESTING SCHEDULE
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has approved restricted stock unit (RSU) grants covering 46,044 shares of common stock for 149 new non-executive employees, issued under the company's Nasdaq inducement listing rule.
Details of the Grant
On July 21, 2026, the Compensation Committee of Guardant Health's Board of Directors approved the grant of RSUs representing 46,044 shares of common stock to 149 new non-executive employees, with a grant date of August 3, 2026. The awards were issued under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan").
The RSUs were granted as inducements material to the employees entering into employment with Guardant, in accordance with Nasdaq Listing Rule 5635(c)(4), which permits companies to make equity grants to new hires outside of shareholder-approved equity plans as a hiring incentive.
What Is the Inducement Plan?
The Inducement Plan is used exclusively for granting equity awards to individuals who were not previously employees of Guardant, or who return following a bona fide period of non-employment. It serves as a material inducement for these individuals to accept employment with the company, consistent with Nasdaq Listing Rule 5635(c)(4).
One-third of the shares underlying each RSU award vest annually on the anniversary of the vesting commencement date, contingent on continued employment with Guardant at each vesting milestone. All grants remain subject to the terms of the Inducement Plan and the applicable RSU award agreement.
About Guardant Health
Founded in 2012, Guardant Health is a leading precision oncology company focused on guarding wellness and giving people more time free from cancer. The company is transforming patient care and accelerating new cancer therapies through advanced blood and tissue tests, real-world data, and AI analytics.
Guardant's tests support outcomes across all stages of cancer care, including early screening, recurrence monitoring in early-stage cancer, and treatment selection for patients with advanced-stage disease.
Key Takeaways
- →Guardant Health's Compensation Committee approved RSU grants for 46,044 shares to 149 new non-executive employees.
- →The grants were approved on July 21, 2026, with an official grant date of August 3, 2026.
- →Awards were issued under the company's 2023 Employment Inducement Incentive Award Plan.
- →Grants comply with Nasdaq Listing Rule 5635(c)(4), which governs inducement equity awards for new hires.
- →RSUs vest in equal one-third installments annually, contingent on continued employment.
- →The move reflects continued workforce expansion at the precision oncology company.
Tags:
Guardant Health
Nasdaq Listing Rule 5635(c)(4)
RSU Grants
Inducement Plan
Precision Oncology
Employee Compensation
Health Technology
Corporate Governance
